Coming December: ASH publishes its late-breaking abstracts. We’ll add the organizations presenting them.

Roche at ASH 2026

Dec 12–15, 2026 New Orleans, LA ~30k attendees Website

Roche brings 2 presentations to ASH 2026 in New Orleans. Its program centres on lymphoma, with research on gene therapy for hemophilia A as well. It supports a symposium on sequencing bispecifics in DLBCL and presents work on standardizing response criteria from PET and CT scans.

OrganizationASH 2026 Attendance
Roche
Basel, Switzerland
Large pharma
Swiss pharmaceutical and diagnostics company; its hematology medicines include bispecific antibodies for lymphoma.
Symposium
Fri Dec 11
7:00pm–10:00pm
Advancing the DLBCL Paradigm: Sequencing Bispecifics in Optimizing Patient Care
Where bispecific antibodies fit in diffuse large B-cell lymphoma, weighed against CAR-T by patient fitness, access, and T-cell health.
Lymphoma · New drugs

Explore the full ASH 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in New Orleans. Leave your work email and we’ll be in touch.

Privacy

Download the full ASH 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Roche

Tell us what you sell and we’ll find the people at Roche most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction